E
Evotec SE (EVO)
NMS – Real Time Price. Currency in USD
3.00
-0.06 (-1.96%)
At close: May 12, 2026, 4:00 PM EDT
3.00
0.00 (0.00%)
After-hours: May 12, 2026, 4:52 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
3.00
-0.06 (-1.96%)
At close: May 12, 2026, 4:00 PM EDT
3.00
0.00 (0.00%)
After-hours: May 12, 2026, 4:52 PM EDT
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. In addition, it has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. Further, the company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
| Name | Position |
|---|---|
| Dr. Christian Dargel | EVP Global Head of Legal & Compliance |
| Dr. Christian Wojczewski Ph.D. | CEO & Chairperson of the Management Board |
| Dr. Cord Dohrmann Ph.D. | Chief Scientific Officer & Member of Management Board |
| Dr. David Hallet | Executive Vice President |
| Dr. Ian M. Hunneyball | Senior Vice President of Programme Management & Clinical Operations |
| Dr. Ingrid Mller | COO & Member of Management Board |
| Dr. Sarah Fakih | Executive VP, Head of Global Communications & Investor Relations |
| Ms. Aurelie Dalbiez | Chief People Officer & Member of Management Board |
| Ms. Claire Hinshelwood | CFO & Member of Management Board |
| Uwe Andag | EVP Head of Metabolic Diseases |
| Date | Type | Document |
|---|---|---|
| 2026-05-06 | 6-K | tm2613738d1_6k.htm |
| 2026-04-24 | 6-K | tm2612670d1_6k.htm |
| 2026-04-08 | 20-F | evo-20251231x20f.htm |
| 2026-04-07 | 6-K | tm2611286d1_6k.htm |
| 2026-03-10 | 6-K | tm268431d1_6k.htm |
| 2026-01-16 | 6-K | tm263400d1_6k.htm |
| 2026-01-13 | 6-K | tm263046d1_6k.htm |
| 2026-01-08 | 6-K | tm262587d1_6k.htm |
| 2026-01-06 | 6-K | tm262169d1_6k.htm |
| 2026-01-02 | 6-K | tm261640d2_6k.htm |